...Thanks for that introduction, Matt. Today, I'm excited to announce our plans to build a leading anti-FcRn franchise consisting of batoclimab and another asset of ours under development, IMVT-1402. I'll be making some forward-looking statements, and I direct investors to this slide filed with our 8-K today and posted on our website. Everything at Immunovant starts with our vision to enable normal lives for people with autoimmune diseases. We want to bring therapies to market that improve substantially on the standard of care and provide differentiated benefits versus other therapies in development. With that in mind, I'm excited to unveil, for the first time today, IMVT-1402. And as I think you'll come to see as we progress through the presentation, 1402 is a truly exciting new product that we believe will dramatically expand Immunovant's clinical and commercial opportunity, and together with batoclimab enable us to deliver a leading FcRn franchise. 1402 is a fully human monoclonal antibody...
